NeoGenomics: Decent Fundamentals, But Still Overvalued

Today, I want to take a look at NeoGenomics (NASDAQ: NEO ). We will review their Q4'24 results and assess their position in the market, understanding how much head-room the company has for growth. After that, we will take a quick lookI am a value dividend investor with an eye for heavy long term compounding. Whenever I see a company that is heavily undervalued with large upside, I always jump in to take my share of the riches. I have been investing since I can remember, specialising in long term growth divi ...